Mersana’s fleximer immunoconjugate shows potent activity in low HER2-expressing tumor models
XMT-1522 is based on the company’s Fleximer immunoconjugate technology that carries an average of 15 proprietary auristatin payload molecules. Optimized for payload delivery, the conjugate uses a new
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.